Form 4: Rigel Pharmaceuticals Director Walter H. Moos Reports Acquisition of Shares and Stock Options

Director Walter H. Moos reports acquisition of Rigel Pharmaceuticals shares and stock options on May 25, 2024.

Summary

• On May 25, 2024, Walter H. Moos, a director of Rigel Pharmaceuticals, reported acquiring 25,000 shares of common stock through the vesting of restricted stock units.
• These restricted stock units will fully vest prior to the company's next Annual Meeting, contingent upon continuous service on the Board of Directors.
• Moos also acquired stock options for 30,000 shares at an exercise price of $0.9075, vesting monthly over one year from the grant date, also subject to continuous service on the Board.
• Following these transactions, Moos beneficially owns 102,222 shares of common stock and 30,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of insider transactions. The acquisition of shares and options could be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director may signal confidence in the company's future prospects.
• The vesting schedule tied to continuous service on the Board of Directors aligns the director's interests with the company's long-term success.

Future Outlook

The restricted stock units will fully vest prior to the company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding insider ownership.
• The vesting conditions tied to continuous service align the director's interests with the company's long-term performance, potentially benefiting shareholders.

Key Dates